Mesenchymal stromal cells augment CD4+ and CD8+ T-cell proliferation through a CCL2 pathway

Cytotherapy

Volumn 15, Issue 10, 2013, Pages 1195-1207

  Zhou, Yingzhe ^a   Day, Andrea ^a   Haykal, Siba ^a   Keating, Armand ^b   Waddell, Thomas K ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Allogeneic MLR; Immunostimulation; Immunosuppression; MSC; T cells

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALLOGENEIC MLR; IMMUNOSTIMULATION; IMMUNOSUPPRESSION; MSC; T CELLS;

ANIMALS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL GROWTH PROCESSES; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; IMMUNOMODULATION; LYMPHOCYTE CULTURE TEST, MIXED; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 84883212311     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.05.009     Document Type: Article

References (36)

1. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006, 13:419-425.
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
3. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
4. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
5. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
6. Ren G., Su J., Zhang L., Zhao X., Ling W., L'Huillie A., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27:1954-1962.
7. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
8. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
9. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
10. Yang S.H., Park M.J., Yoon I.H., Kim S.Y., Hong S.H., Shin J.Y., et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009, 41:315-324.
11. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
12. Groh M.E., Maitra B., Szekely E., Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005, 33:928-934.
13. Sheng H., Wang Y., Jin Y., Zhang Q., Zhang Y., Wang L., et al. Acritical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008, 18:846-857.
14. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007, 110:91-100.
15. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
16. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
17. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83:71-76.
18. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
19. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
20. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
21. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
22. Prigozhina T.B., Khitrin S., Elkin G., Eizik O., Morecki S., Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008, 36:1370-1376.
23. Kotton D.N., Ma B.Y., Cardoso W.V., Sanderson E.A., Summer R.S., Williams M.C., et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001, 128:5181-5188.
24. Shi Y., Su J., Roberts A.I., Shou P., Rabson A.B., Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012, 33:136-143.
25. Comoli P., Ginevri F., Maccario R., Avanzini M.A., Marconi M., Groff A., et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008, 23:1196-1202.
26. Grove D.A., Xu J., Joodi R., Torres-Gonzales E., Neujahr D., Mora A.L., et al. Attenuation of early airway obstruction by mesenchymal stem cells in a murine model of heterotopic tracheal transplantation. J Heart Lung Transplant 2011, 30:341-350.
27. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
28. Najar M., Rouas R., Raicevic G., Boufker H.I., Lewalle P., Meuleman N., et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009, 11:570-583.
29. Hwang J.H., Shim S.S., Seok O.S., Lee H.Y., Woo S.K., Kim B.H., et al. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. JKorean Med Sci 2009, 24:547-554.
30. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994, 91:3652-3656.
31. Xu L.L., Warren M.K., Rose W.L., Gong W., Wang J.M. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. JLeukoc Biol 1996, 60:365-371.
32. Rafei M., Campeau P.M., Wu J.H., Birman E., Forner K., Boivin M.N., et al. Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. JImmunol 2009, 182:2620-2627.
33. Loetscher P., Seitz M., Baggiolini M., Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. JExp Med 1996, 184:569-577.
34. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. JImmunol 2009, 182:5994-6002.
35. Karpus W.J., Lukacs N.W., Kennedy K.J., Smith W.S., Hurst S.D., Barrett T.A. Differential CC chemokine-induced enhancement of T helper cell cytokine production. JImmunol 1997, 158:4129-4136.
36. Zha X., Yin Q., Tan H., Wang C., Chen S., Yang L., et al. Alteration of the gene expression profile of T-cell receptor alphabeta-modified T-cells with diffuse large B-cell lymphoma specificity. Hematology 2013, 18:138-143.